Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Headline
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, clinical data and labeling for…
Headline
The AHA will host a webinar on Nov. 12 at 2 p.m. ET exploring the AHA’s Economic Impact of Disparities in Health Outcomes Resource Guide which helps hospital…
Headline
A multistate cyclospora outbreak linked to iceberg lettuce has been declared over, the Centers for Disease Control and Prevention and Food and Drug…
Perspective
Public
Twenty-five years ago, our nation experienced one of the darkest days in its history. The terrorist attacks of Sept. 11, 2001, took thousands of innocent lives…
Headline
The Federal Office of Rural Health Policy’s Rural Health Redesign Center will host a webinar on Sept. 24 at 2 p.m. ET, where hospital CEOs will discuss the…
Headline
Joy A. Rhoden, AHA senior vice president and executive director of health outcomes and care transformation, explores the economic impact of health disparities…